Eyebrow THE POWER AND SPEED OF GENETIC ENGINEERING Headline Novavax addresses urgent global public health needs with innovative technology Text Recombinant Nanoparticle Vaccine Technology Our recombinant nanoparticle vaccine technology combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic particles that target a variety of viral pathogens. Our recombinant vaccine engineering takes a new approach to provide robust and functional immunity, which may be more efficacious than naturally occurring immunity or traditional vaccines. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. How we create our nanoparticles Image Select genetic sequences to encode vaccine antigens Image Genes are cloned into baculovirus (BV) Image BV infects Sf9 insect cells Image Antigens are expressed and purified as multimeric nanoparticles Image Immunogenic particle with antigens in native configuration are created Ability to tailor our vaccines to key components of pathogens to enhance functional immunity and lead to better protection against infection and disease. Promote superior immunogenicity and better functional immunity via our Sf9/BV insect cell platform to efficiently express large antigens and particles. Ability to manufacture and produce proteins that are properly folded and modified, which can be critical for functional, protective immunity. Ability to leverage our proprietary vaccine technology, which produces highly immunogenic vaccines in a scalable, efficient recombinant vaccine production system. Novavax’ recombinant protein nanoparticle vaccine technology Eyebrow POWERED BY AN INNOVATIVE FORMULATION Main Content Matrix-M™ adjuvant technology stimulates strong responses Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date. Image Matrix-M™ adjuvant Image Induces the influx of antigen-presenting cells (APC), which enhance activated T cell, B cell, and APC populations. Image Increases neutralizing antibodies and induces long-lasting memory B cells, which enhance B-cell immunity and recruit and increase the frequency of CD4+ and CD8+ T cells that enhance T-cell immunity. Image Matrix-M provides strong and long-lasting immune responses, which can enable dose-sparing. Matrix-M is composed of particles based on saponin extracted from the Quillaja saponaria Molina bark together with cholesterol and phospholipid. Matrix-M enhanced biologic functions to generate potent, robust, and long-lasting protective immune responses. Matrix-M can lower the dose of antigen required to achieve the desired immune response, which results in fewer vaccine doses needed and increased supply and manufacturing capacity. Main navigation ABOUT US OUR PIPELINE SCIENCE AND TECHNOLOGY RESOURCES CAREERS Utility navigation FOR INVESTORS Corporate Governance Stock Information Events SEC Filings Analyst Coverage Investor Relations Contact Annual Report Investor Presentation NEWS COVID-19 Candidate Updates Press Releases & Statements Novavax in the News Join the Press Release List Press Center Contact Us CONTACT US 21 Firstfield Road Gaithersburg, MD 20878 (240) 268-2000 SOCIAL Footer navigation Privacy Policy Terms and Conditions Pay Transparency Nondiscrimination Provision Purchase Order Terms and Conditions This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings. Accept